Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05066477
Other study ID # CALGO-OST
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 22, 2021
Est. completion date July 3, 2025

Study information

Verified date September 2023
Source Hofseth Biocare ASA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of salmon bone meal in preventing bone loss among perimenopausal women with reduced bone mass density.


Description:

The current study is part of a larger project called the CalGo-project. The overall purpose of the study is to use bone meal from salmon to promote skeletal health. Specifically, the effect of salmon bone meal on bone mass density among perimenopausal women (age ≥ 50 years) with osteopenia is investigated over a time period of 2 years. Salmon bone meal is composed of a natural microcrystalline hydroxyapatite form of calcium and phosphorus, collagen type 2. Past literature on mammalian sources of bone meal has indicated that this form of calcium is superior in terms of preserving bone mass density compared to traditional calcium supplements. Preserving bone mass is essential to reduce the risk of future fragility fractures. Osteopenia is a condition of reduced bone mass density and bone quality which can indicate the later onset of clinical osteoporosis. Both are conditions associated with a significant risk of fragility fractures, which are a major global health burden. Bone mass density is measured using dual-energy X-ray absorptiometry. Markers of bone formation P1NP and CTX-1 will be measured in serum samples of participants. 100 potential participants will be screened for eligibility. Participants who meet the eligibility criteria will be randomized in a double-blind manner to receive 4 capsules daily of salmon bone meal enriched with Vitamin D3 per capsule.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date July 3, 2025
Est. primary completion date July 3, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years and older
Eligibility Inclusion Criteria: - Female gender - = 50 years of age - DXA T-score of > -2.5 standard deviations, but = -1 (osteopenic range) - Steady state body weight 1 month before study commencement date - No contraindications for intake of the interventional product, including a prior diagnosis of fish allergy. - Familiar with the Norwegian language, both in writing and orally Exclusion Criteria: - A diagnosis of osteoporosis (BMD T-score = -2.5 SD as diagnosed by DXA), or any previously diagnosed fragility fractures on a background of osteoporosis. - Use of drugs known to affect bone metabolism, including: - Glucocorticoids - Thyroid hormones - Hormone replacement therapy taken continuously for a duration of less than 6 months. - Long-term heparin therapy - Anti-convulsive drugs - Long-term proton pump inhibitor treatment - Lithium - Anti-osteoporotic drugs - Cancer therapy - Selective estrogen receptor modulators. - Any disease or medical condition known to affect bone tissue, including neoplasia with or without metastasis, Paget's disease of bone, Osteomalacia, or any other disease deemed relevant by the PI. - Gastrointestinal diseases or disturbances potentially affecting absorption of nutrients, including Crohn's disease and Celiac disease. - Hypersensitivity to ingredients in the interventional product, including fish allergy. - Not willing to participate in the study. - Other reasons that the PI deems it necessary to exclude the subject.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
CalGo
CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and phosphorus. Furthermore it contains collagen type 2 and is enriched with vitamin D3.
Other:
Placebo
Pure maltodextrin

Locations

Country Name City State
Norway Hofseth Biocare ASA Ålesund Møre Og Romsdal
Norway Kristiansund Hospital Kristiansund Møre Og Romsdal
Norway Lovisenberg Diakonale Sykehus Oslo

Sponsors (2)

Lead Sponsor Collaborator
Hofseth Biocare ASA Møre og Romsdal Hospital Trust

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in Bone Mass Density (BMD) of the femoral neck at Month 12, and Month 24. Change in BMD of the femoral neck is assessed based on dual-energy X-ray absorptiometry T-scores. Baseline, 12 Months, and 24 Months.
Secondary Mean change in Bone Mass Density (BMD) of the lumbar spine (L1-L4) at Month 12, and Month 24. Change in BMD of the lumbar spine segments L1-L4 is assessed based on dual-energy X-ray absorptiometry T-scores. Baseline, 12 Months, and 24 Months
Secondary Mean change in Bone Mass Density (BMD) of the distal forearm at Month 12, and Month 24. Change in BMD of the distal forearm (distal radius) is assessed based on dual-energy X-ray absorptiometry T-scores. Baseline, 12 Months, and 24 Months
Secondary Change in serum levels of markers of bone formation at Month 6, Month 12, and Month 24. Serum markers of bone formation are analyzed in frozen serum samples from participants. Baseline, 6 Months, 12 Months, and 24 Months.
Secondary Change from Baseline in self-assessed quality of life on the EuroQol-5 Dimensions-3 Levels (EQ-5D-3L) instrument at Month 24. 5Q-5D-3L is a standardized instrument used to measure generic quality of life based on five distinct dimensions. EQ-5D-3L contains two parts. The first part contains five questions that the individual must answer and includes mobility (walking), self-care, usual activities, pain/discomfort, and anxiety/depression. For each item, there are three possible answers. Results are reported as a five-digit number ranging from 11111 (best health status) to 33333 (worst health status). Several methods exist for analysing these number profiles, and it is possible to convert the number profile into an index number. The second part is the EQ-VAS, where the patient self-assesses their overall health on a visual analogue scale (VAS), with 100 indicating the best health status. Baseline and 24 Months
Secondary Difference in number of Adverse Events between the study groups. To assess whether there is a statistically significant difference in the number of adverse events between the two study groups (CalGo [Salmon Bone Meal] and Placebo). 3 Months, 6 Months, 12 Months, 18 Months, 24 Months
Secondary Difference in number of fractures between the two study groups. To assess whether there is a statistically significant difference in the number of fractures between the two study groups (CalGo [Salmon Bone Meal] and Placebo). 3 Months, 6 Months, 12 Months, 18 Months, 24 Months
Secondary Difference in urine calcium in a spot urine sample between the two study groups. Amount of calcium will be measured in spot urine samples from participants. Baseline, 12 Months, and 24 Months.
See also
  Status Clinical Trial Phase
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT01439139 - Bone UltraSonic Scanner (BUSS): Validation Study N/A
Not yet recruiting NCT01397838 - Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women Phase 1
Completed NCT01222026 - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Phase 4
Completed NCT01152580 - Melatonin Osteoporosis Prevention Study Phase 1
Completed NCT00789425 - Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women Phase 2
Completed NCT00463268 - Osteoporosis Prevention With Low Dose Alendronate Phase 3
Completed NCT00655681 - Prevention of Post Operative Bone Loss in Children N/A
Completed NCT00798473 - Zoledronate for Osteopenia in Pediatric Crohn's Phase 3
Active, not recruiting NCT00076050 - Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms Phase 3
Completed NCT00226031 - Optimal Management of Women With Wrist Fractures N/A
Enrolling by invitation NCT04752098 - A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method N/A
Completed NCT04720833 - Effect of Dried Plum on Bone and Markers of Bone Status in Men N/A
Recruiting NCT05541432 - Finding the Optimal Resistance Training Intensity For Your Bones N/A
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Completed NCT05457036 - Evaluation of the Effect of Spry Belt Treatment on Bone Turnover Marker Profile N/A
Completed NCT04040010 - The Effects of Bovine Colostrum in Bone Metabolism in Humans N/A
Completed NCT02731820 - Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia N/A
Completed NCT05721014 - Effects of OsteoStrong vs. Individually Adapted and Combined Training on Bone Health N/A